Sofosbuvir as a potential option for the treatment of COVID-19

Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Nourian, Anahid, Khalili, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2020
Materias:
Correspondence/Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569608/
https://www.ncbi.nlm.nih.gov/pubmed/32420958
http://dx.doi.org/10.23750/abm.v91i2.9609
_version_ 1783596763353972736
author Nourian, Anahid
Khalili, Hossein
author_facet Nourian, Anahid
Khalili, Hossein
author_sort Nourian, Anahid
collection PubMed
description Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies. (www.actabiomedica.it)
format Online
Article
Text
id pubmed-7569608
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-75696082020-10-21 Sofosbuvir as a potential option for the treatment of COVID-19 Nourian, Anahid Khalili, Hossein Acta Biomed Correspondence/Case Reports Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies. (www.actabiomedica.it) Mattioli 1885 2020 2020-05-11 /pmc/articles/PMC7569608/ /pubmed/32420958 http://dx.doi.org/10.23750/abm.v91i2.9609 Text en Copyright: © 2020 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Correspondence/Case Reports
Nourian, Anahid
Khalili, Hossein
Sofosbuvir as a potential option for the treatment of COVID-19
title Sofosbuvir as a potential option for the treatment of COVID-19
title_full Sofosbuvir as a potential option for the treatment of COVID-19
title_fullStr Sofosbuvir as a potential option for the treatment of COVID-19
title_full_unstemmed Sofosbuvir as a potential option for the treatment of COVID-19
title_short Sofosbuvir as a potential option for the treatment of COVID-19
title_sort sofosbuvir as a potential option for the treatment of covid-19
topic Correspondence/Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569608/
https://www.ncbi.nlm.nih.gov/pubmed/32420958
http://dx.doi.org/10.23750/abm.v91i2.9609
work_keys_str_mv AT nouriananahid sofosbuvirasapotentialoptionforthetreatmentofcovid19
AT khalilihossein sofosbuvirasapotentialoptionforthetreatmentofcovid19

Ejemplares similares